알림

GSK (GLAXF)

OTC Markets OTCPK: GLAXF · 실시간 가격 · USD

25.42

+0.00 (0.00%)

종가 기준: Aug 13, 2026, 2:11 PM

0.00% (1D)

매수호가	n/a
시가총액	101.82B
매출 (ttm)	33.2B
순이익 (ttm)	4.82B
베타	0.29
EPS (ttm)	1.59
P/E (ttm)	15.99
선행 P/E	11.55
P/B (ttm)	4.29
P/S (ttm)	3.07
Earnings Date	Oct 28, 2026

매도호가	n/a
거래량	150
평균 거래량 (20일)	729
시가	24.29
전일 종가	25.42
일중 범위	24.29 - 24.29
52주 범위	18.99 - 31.48
애널리스트	n/a
목표주가	n/a
배당	$0.92 (3.61%)
배당락일	2026년 8월 13일

GLAXF 소개

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respirator...

[더 보기]

산업 Drug Manufacturers - General

섹터 Healthcare

IPO 일자 Jan 5, 2010

직원 수 66,841

상장 거래소 OTC Markets OTCPK

티커 GLAXF

웹사이트 https://www.gsk.com

전체 기업 정보

재무 실적

2025년 GSK의 매출은 32.67B로, 전년 31.38B 대비 4.11% 증가했습니다. 순이익은 5.72B로, 121.98% 증가했습니다.

재무제표

다음 실적 발표

GSK의 실적 발표 예정일은 Oct 28, 2026, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Insider Monkey

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover rea...

3일 전 · 24/7 Wall St.

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer....

6일 전 · Bloomberg

Trump Plans to Sign Order on Splitting Up Combined Measles Shot

(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, accordin...

1주 전 · Zacks

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

2주 전 · Simply Wall St.

GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics

GSK (LSE:GSK) plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK. The site is expected to accommodate more than 1,000 scientists and support closer work with nearb...

2 페이지 중 1

GSK (GLAXF)

GLAXF 소개

재무 실적